Sphingosine-1-phosphate receptor 3 regulates the transendothelial transport of HDL and LDL in opposite ways.

HDL LDL SR-BI endothelium sphingosine-1-phosphate

Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
18 Dec 2023
Historique:
received: 27 04 2023
revised: 11 07 2023
accepted: 16 12 2023
medline: 18 12 2023
pubmed: 18 12 2023
entrez: 18 12 2023
Statut: aheadofprint

Résumé

The entry of lipoproteins from blood into the arterial wall is a rate-limiting step in atherosclerosis. It is controversial whether this happens by filtration or regulated transendothelial transport.Because sphingosine-1-phosphate (S1P) preserves the endothelial barrier, we investigated in vivo and in vitro, whether S1P and its cognate S1P receptor 3 (S1P3) regulate the transendothelial transport of lipoproteins. Compared to apoE-haploinsufficient mice (CTRL), apoE-haploinsufficient mice with additional endothelium specific knock-in of S1P3 (S1P3-iECKI) showed decreased transport of LDL and Evan's Blue but increased transport of HDL from blood into the peritoneal cave. After 30 weeks of high-fat diet feeding, S1P3-iECKI mice had lower levels of non-HDL-cholesterol and less atherosclerosis than CTRL mice. In vitro, stimulation with an S1P3 agonist increased the transport of 125I-HDL but decreased the transport of 125I-LDL through human aortic endothelial cells (HAECs). Conversely, inhibition or knock-down of S1P3 decreased the transport of 125I-HDL but increased the transport of 125I-LDL. Silencing of SCARB1 encoding scavenger receptor B1 (SR-BI) abrogated the stimulation of 125I-HDL transport by the S1P3 agonist. The transendothelial transport of 125I-LDL was decreased by silencing of SCARB1 or ACVLR1 encoding activin-like kinase 1 but not by interference with LDLR. None of the three knock-downs prevented the stimulatory effect of S1P3 inhibition on transendothelial 125I-LDL transport. S1P3 regulates the transendothelial transport of HDL and LDL oppositely by SR-BI-dependent and SR-BI-independent mechanisms, respectively. This divergence supports a contention that lipoproteins pass the endothelial barrier by specifically regulated mechanisms rather than passive filtration.

Identifiants

pubmed: 38109696
pii: 7477107
doi: 10.1093/cvr/cvad183
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Srividya Velagapudi (S)

Institute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Switzerland.

Dongdong Wang (D)

Institute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Switzerland.

Francesco Poti (F)

Department of Medicine and Surgery - Unit of Neurosciences, University of Parma, Parma, Italy.
Department of Biomedical, Metabolic and Neural Sciences - Unit of Endocrinology, University of Modena and Reggio Emilia, Modena, Italy.

Renata Feuerborn (R)

Central Laboratory Facility, University Hospital of Münster, Germany.

Jerome Robert (J)

Institute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Switzerland.

Eveline Schlumpf (E)

Institute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Switzerland.

Mustafa Yalcinkaya (M)

Institute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Switzerland.

Grigorios Panteloglou (G)

Institute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Switzerland.

Anton Potapenko (A)

Institute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Switzerland.

Manuela Simoni (M)

Department of Biomedical, Metabolic and Neural Sciences - Unit of Endocrinology, University of Modena and Reggio Emilia, Modena, Italy.

Lucia Rohrer (L)

Institute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Switzerland.

Jerzy-Roch Nofer (JR)

Central Laboratory Facility, University Hospital of Münster, Germany.
Institute of Laboratory Medicine, Marien-Hospital Osnabrück, Niels-Stensen-Kliniken, Osnabrück, Germany.

Arnold von Eckardstein (A)

Institute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Switzerland.

Classifications MeSH